Momenta Pharmaceuticals (Momenta Pharmaceuticals) Debt-to-Equity : 0.09 (As of Jun. 2020)

View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Debt-to-Equity?

Momenta Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $5.73 Mil. Momenta Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $31.35 Mil. Momenta Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $395.32 Mil. Momenta Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2020 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Momenta Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

MNTA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.04 Med: 0.05 Max: 0.29
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Momenta Pharmaceuticals was 0.29. The lowest was -0.04. And the median was 0.05.

MNTA's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.285 vs MNTA: 0.09

Momenta Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Momenta Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Debt-to-Equity Chart

Momenta Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

Get a 7-Day Free Trial

0.09

Momenta Pharmaceuticals Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Debt-to-Equity	Get a 7-Day Free Trial															0.29	0.15	0.09	0.09	0.09

Competitive Comparison of Momenta Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Momenta Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Debt-to-Equity falls into.

Momenta Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Momenta Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.448	+	34.306)	/	454.46
	=	0.09

Momenta Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.733	+	31.354)	/	395.317
	=	0.09

Momenta Pharmaceuticals (NAS:MNTA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Momenta Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.momentapharma.com

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Executives

Bruce Downey	director
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner	director	C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo	officer: SVP, Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon	officer: Chief Financial & Bus. Officer	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier	officer: Chief Mfg and Program Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello	officer: Chief HR and Inf. Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning	officer: Chief Scientific Officer	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska	officer: Chief Accounting Officer (PAO)	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler	director, officer: President & CEO